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This systematic review, stimulated by inconsistency in secondary evidence, reports the benefits and harms of breast cancer
(BC) screening and their determinants according to systematic reviews. A systematic search, which identified 9,976 abstracts,
led to the inclusion of 58 reviews. BC mortality reduction with screening mammography was 15–25% in trials and 28–56% in
observational studies in all age groups, and the risk of stage III+ cancers was reduced for women older than 49 years.
Overdiagnosis due to mammography was 1–60% in trials and 1–12% in studies with a low risk of bias, and cumulative false-
positive rates were lower with biennial than annual screening (3–17% vs 0.01–41%). There is no consistency in the reviews’
conclusions about the magnitude of BC mortality reduction among women younger than 50 years or older than 69 years, or
determinants of benefits and harms of mammography, including the type of mammography (digital vs screen-film), the number
of views and the screening interval. Similarly, there was no solid evidence on determinants of benefits and harms or BC
mortality reduction with screening by ultrasonography or clinical breast examination (sensitivity ranges, 54–84% and 47–69%,
respectively), and strong evidence of unfavourable benefit-to-harm ratio with breast self-examination. The reviews’ conclusions
were not dependent on the quality of the reviews or publication date. Systematic reviews on mammography screening, mainly
from high-income countries, systematically disagree on the interpretation of the benefit-to-harm ratio. Future reviews are
unlikely to clarify the discrepancies unless new original studies are published.
Introduction
The traditional evidence-based medicine pyramid places system-
atic reviews with meta-synthesis on the pinnacle of a hierarchy of
evidence. The recently proposed update of the pyramid applies
systematic reviews as a lens through which other types of studies
should be appraised, considering synthesised evidence as a tool for
stakeholders.1 But does this lens always provide the same image,
and if not, what can affect the conclusions of systematic reviews?
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Many reviews on benefits and harms of breast cancer
screening (BCS) have been published over several years. Some
of these reviews were used as a basis for developing national
or international guidelines, leading to inconsistent recommen-
dations. In a set of systematic reviews, we summarise the data
from reviews on four screening approaches – screening mam-
mography, ultrasonography, clinical breast examination (CBE)
and breast self-examination (BSE) – or their combinations,
among the general population. To our knowledge, no study
has previously synthesised the results from systematic reviews
on determinants of benefits and harms, participation rate, or
cost-effectiveness of BCS approaches or explored the possible dif-
ferences in the conclusions of systematic reviews on this topic.
In this review, we aim to report:
(1) Variability in the outcomes of the reviews (mortality
reduction, overdiagnosis, false-positive rates (FPR), mortality
induced and intermediate outcomes of BCS);
(2) Variability in the determinants of benefits and harms;
(3) Review characteristics that explain the variability in the
outcomes and derived conclusions.
Methods
The design of this study was reported in the published
protocol,2 and registered with the International prospective reg-
ister of systematic reviews (PROSPERO, #CRD42016050764).
We systematically searched the PubMed via Medline, Scopus,
Embase and Cochrane databases in August 2016 and conducted
updates and searches for grey literature in February 2017 and
again in April 2018 (Appendix 1).
Following the protocol, we excluded reviews not using a
systematic (reproducible) literature search. Deviating from the
protocol, we included two reviews on which consensus was
not reached after two rounds of discussions. For each of the
included reviews, we tabulated the outcomes, the score by the
Assessing the Methodological Quality of Systematic Reviews
(AMSTAR) checklist,3 the limitations of the reviews, and the
limitations of the original studies (if their quality was assessed
by the reviews and considered in the conclusions). We also
narratively summarised the outcomes of the reviews that
scored two or higher on the AMSTAR checklist, considering
the reviews with lower scores as non-systematic. For the
reviews with updates, we synthesised the evidence from the
most recent publication, separately reporting the conclusions
of the previous versions.
The uni- and multi-nomial regressions were run in RStu-
dio to assess an impact of factors on the AMSTAR quality
score and conclusions of the reviews regarding mammography
screening.
Results
We identified 9,976 abstracts through our systematic search and
228 additional reviews through a non-systematic search (Fig. 1).
The inter-rater reliability between two reviewers for decisions on
full-text inclusion was 85% (Cohen’s kappa = 0.63; substantial
agreement). The excluded reviews are indicated in Appendix 2.
The 58 included reviews, of which 52 were without updates
(Appendix 3), reported data on benefits (n = 30), harms
(n = 9), or both (n = 19). Most reviews on benefits and harms
of BCS were not limited to a particular geographical region or
setting; the others searched for studies comparable to the tar-
get countries, such as the UK,4–6 the USA,7–13 Canada,14–17
Australia,18 the Republic of Korea,19 or Japan,20 or limited the
literature search to a specific region (Asia in one systematic21
and Europe in five narrative reviews22–26).
We did not identify systematic reviews reporting the benefits
or harms of mammography screening in low- and middle-income
countries (LMICs);27 BSE outcomes were reported for China and
the Philippines, and CBE outcomes for India. Trials reporting
final outcomes of mammography screening, cited in the reviews,
were conducted only in, and observational evidence was mainly
from, high-income jurisdictions (Appendix 3). A fixed-effects
model was used in some of the reviews assessing the clinical out-
comes of BCS programmes, including the cluster of Cochrane
reviews,20,26,28–32 which may signify an assumption of no cross-
population differences in the interventions and outcomes.
The structure of the identified outcomes reported in the
reviews on benefits and harms of BCS by screening modality
is presented in Figure 2.
Screening mammography
Benefits of screening mammography among all age
groups. There is consistency on breast cancer mortality (BCM)
reduction among meta-analyses (Fig. 3a) and reviews without
meta-synthesis (Appendix 4), but no consistency in the interpre-
tation of the size of the effect, the importance of the effect and
conclusions on screening with the observed risk or odds ratios
What’s new?
Multiple reviews of the benefits and harms of mammography have been used to inform breast cancer screening guideline
development. This process, however, has led to inconsistent screening recommendations. Here, synthesis of results from
systematic reviews based on original evidence of determinants of mammography benefits and harms reveals irregularities in
data on magnitude of breast cancer reduction obtained with screening mammography. Evidence on determinants of benefits
and harms of ultrasonography and clinical breast examination was lacking. Inconsistency in reviews’ conclusions was affected
by characteristics of the original evidence, indicating that new original studies are needed to clarify discrepancies in screening
recommendations.
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being justified. The mean size of effect pooled from randomised
controlled trials (RCTs) is 15–25%,6,9,11,16,19,20,25,30,33–37 from
models/estimates is 11–33%,33–35 and from observational/
population evidence is 28–56%.9,25,36 The Cochrane review
reported statistically non-significant all-cancer mortality reduc-
tion. The all-cause mortality reduction was also statistically
non-significant in all the included reviews (Appendix 4).
Overall, the reviews of screening mammography reported
high variability of accuracy and intermediate outcomes includ-
ing sensitivity, size and proportion of small and advanced
tumours at diagnosis, proportional interval cancer rate, interval
cancer ratio and positive predictive value (PPV). The most
frequently reported outcomes, sensitivity and PPV, had ranges
of 51–97% and 2–22%, respectively (Appendix 5).
Although screen-detected tumours may be slow-growing32
and thus lead to overdiagnosis,8 tumour size is considered one
of the most potent predictors of tumour behaviour in breast
cancer (BC).38 The reviews were not fully consistent in conclud-
ing that mammography resulted in stage shift or detection of
smaller tumours.8,12,38–40 We observed that the difference in the
conclusions was related to how the target stage shift was defined
(stage II+ vs stage III+). No statistically significant relative risk
(RR) reduction was observed for shift of stage II+ cancers
(Appendix 5). Risk of stage III+ cancers was reduced with
Figure 1. Reproduced with permission from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA statement, PLoS Med, 2009, Vol. 6, page no. e1000097, doi:10.1371/journal.
pmed1000097 © PRISMA Statement or PRISMA Explanation and Elaboration. [Color figure can be viewed at wileyonlinelibrary.com]
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Mammography
Benefits
Final outcomes*
Intermediary 
outcomes**
Determinants of 
benefits
FM vs DM
Double reading
Screening 
intervals
Population
Countries
Studies
Harms
Final outcomes*
Intermediary 
outcomes**
Determinants of 
harms
Benefits and 
Harms by age 
groups
50 – 69 years old
<50 years old
>69 years old
Ultrasonography
Final outcomes*
Intermediary  
outcomes**
Harms
Clinical Breast 
Examination
Final outcomes*
Intermediary 
outcomes**
Harms
Breast Self 
Examination 
Final outcomes*
Intermediary 
outcomes**
Harms
Figure 2. Legend on next page.
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mammography screening for women older than 49 years (RR,
0.62; 95% confidence interval, 0.46–0.83) compared to no
screening.12
Determinants of benefits of screening mammography. There
was no consistency in the reviews whether digital mammography
has higher or lower accuracy than screen-film mammography
(Appendix 6).13,15,41–43 The reviews suggested that digital
mammography performs better in women younger than
50 years, premenopausal or perimenopausal, with heteroge-
neously or extremely dense breast tissue.15,42 Four reviews con-
cluded on inconsistent evidence on recall rates,13,15,41,43 and one
on shorter examination times with digital mammography.15
The included reviews also compared one- vs. two-view mam-
mography, double vs. single reading and screening with different
intervals (from 12 to ≥36 months). The review by Kerlikowske
et al. (1995) reported similar BCM reduction with one- and
two-view mammography.30 Posso et al. (2017)44 summarising
the evidence from studies where the recall decision was reached
by consensus between two readers concluded on similar detec-
tion and FPR, while Dinnes et al. (2001) suggested that double
reading can improve accuracy compared to single reading if a
positive decision by any of the readers is sufficient for recall.5
Because there were no head-to-head trials comparing effective-
ness of BCS by screening intervals, the reviews based their con-
clusions on indirect comparisons. The conclusions of five reviews
were inconsistent about the sufficiency of the evidence on BCM
differences with annual vs. biennial or triennial screen-
ing.9,11,12,16,30 One review found that younger women (<50 years)
may benefit more from annual screening, but this evidence was
insufficient.9
Besides organisational aspects of screening, the reviews also
considered breast cancer incidence by age, because higher
incidence defined a higher effect of screening, and consistency
of effect by country. Humphrey et al. (2002) reported that the
highest incidence occurred before menopause.45
The review of Myers et al. (2015) suggested that inconsis-
tency in screening outcomes may be higher in the USA, where
there is no single provider for BCS programmes, due to variabil-
ity between patients, clinicians and insurers.11 Meta-regression
analysis of the pooled odds ratios of BCM from case–control
studies on BCS did not vary significantly by country.18
The reviews’ conclusions were affected by the characteristics
of the original evidence included (trials or observational stud-
ies), and by the way the original evidence was analysed and
synthesised. There is no observed relationship between initia-
tion dates of RCTs and the reported BCM reduction.12
According to Kerlikowske et al. (1995), studies initiated before
1980 had lower RR than later studies; the reported confidence
intervals of the pooled risk ratios are much wider for later stud-
ies than for earlier publications.30 Reviews based on observa-
tional evidence report larger BCM reduction than the
conclusions based on data from RCTs, with the lowest impact
on BCM within the best-randomised trials (Appendix 4).
Harms of screening mammography among all age groups. The
main harms reported in the systematic reviews were overdiag-
nosis, overtreatment related to overdiagnosis, FPR, false-
positive biopsies and deaths attributable to radiation induced
breast cancer (Appendix 7). The psychological impact of
screening is not presented here, because this was not included
in the search terms.
Definitions and measurements for overdiagnosis (ranged
0–84%) varied by: type of original evidence, source of cases for
the denominator (unscreened, screened detected, entire follow-
up, etc.), duration of follow up, accounting for ductal carcinoma
in situ (DCIS) and other in situ lesions, adjustment for breast
cancer risk and lead time (Appendix 7). In general, studies using
unscreened population in the denominator report higher overdi-
agnosis and lower rates of overdiagnosis were reported among
the pooled values from RCTs and studies with a low risk of bias
(Fig. 4):6,9–12,16,19,20,28,46 1–12% (2 of 3 reviews).
Four reviews reported a higher risk of lumpectomies and
mastectomies that could be related to a lead-time bias or over-
diagnosis.12,14,28,47 Screen-detected breast cancers were more
frequently treated with radiotherapy,12,28,47 but not with che-
motherapy or hormone therapy.28,47
Similar to overdiagnosis, FPR and rate of false-positive
biopsies varied significantly by screening interval, age of initi-
ation, previous screening experience and source of evidence
(Appendix 7). The ranges of non-cumulative FPR were
6.5–8% with annual screening and 1–11% with biennial
screening (Appendix 7),9,11,47 and of cumulative FPR (after
10 years or lifetime) were 3–63% with annual and 7–60% with
biennial screening9,12,14,16,19,20,28,37,47 (Fig. 5). Two reviews
comparing these screening intervals concluded that FPR
is higher with annual screening.11,12 The ranges for non-
cumulative rate of false-positive biopsies were 2–12% with
annual screening11,12 and 0.07–9% with biennial screening;9,12,14
the cumulative rates (≥10 screenings) were 0.01–41% with
annual screening9,11,47 and 3–17% with biennial screening.9,11,47
In contrast to the other harms, rate of deaths attributable to
radiation was not significant in the reviews reporting on the
topic.12,13,48 Further, the most frequently reported intermediate
Figure 2. Structure of the outcomes of the reviews on benefits and harms of mammography, ultrasonography, clinical breast examination
and breast self-examination. *Final outcomes for the benefits of screening: breast cancer mortality, all-cancer mortality, all-cause mortality;
final outcomes for harms of screening: overdiagnosis, overtreatment, false -positive diagnosis, and radiation -induced deaths. **Intermediary
outcomes for the benefits of screening: sensitivity, size and proportion of small and advanced of tumours at diagnosis, proportional interval
cancer rate, interval cancer ratio, positive predictive value; Intermediary outcomes for the harms of screening: specificity, recall rates.
Abbreviations: FM, field mammography; DM, digital mammography.
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outcomes of harms were specificity (>82% in all the reviews)
and recall rate (3–14%) (Appendix 5).
Determinants of harms of screening mammography. Two
reviews concluded on limited or no evidence whether overdi-
agnosis is higher with annual than biennial screening.9,11 FPR
was considered to be higher with more frequent screen-
ings11,12 and with longer duration of screening.11 FPR was
also higher for the first screen than for subsequent screens,11
in women with a family history of breast cancer and high
breast density, and in women using hormone therapy.12 The
rate of false-positive biopsies per screen decreased with the
availability of previous screening results.11 Radiation-related
harms increased with higher doses of exposure, younger age
at exposure and longer follow-up.47
Similar to benefits, harms were not always consistent by
country. Several reviews suggested that harms related to BCS
may be higher in the USA,7,11,14,20,28 with possible explana-
tions related to different screening and diagnostic guidelines,
shorter screening interval, no national provider for screening
services and health-care provision through private centres.
Benefits and harms of screening mammography by age
groups. Systematic reviews and meta-analyses of the RCTs
show a positive effect (22–35%) of mammography screening on
BCM reduction among women aged 50–69 years compared to
no screening (Fig. 3b, Appendix 4).12,13,16,20,28,30,36 All except
one systematic review of observational evidence report BCM
reduction of 17–49% in this age group.12,18,24,26,36,49
The conclusions and interpretations of the statistical findings
of systematic reviews of either RCTs or observational studies
reporting BCM reduction among women younger than
50 years30,32,45 were and remain inconsistent (Fig. 3c, Appendix
4).9,11,12,20,28,37,49 There was no review reporting all-cancer
Figure 3. Breast cancer mortality reduction among (a) all age groups, (b) 50–69 year-old, (c) <50 year-old, (d ) >69 year-old women.
Duke group (2014): (1) Case–control studies, (2) Incidence – based mortality studies; Gotzsche (2013): (1) All randomised trials; (2) Truly
randomised trials; Canadian task force (2011): (1) All randomised trials; (2) Truly randomised trials; Irvin (2014): (1) Birth cohort comparison;
(2) Geographical comparison; (3) Geographical-Historical Comparisons. [Color figure can be viewed at wileyonlinelibrary.com]
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mortality reduction in this age group, and two meta-analyses
concluding on statistically non-significant reduction in all-cause
mortality.16,37 Seven reviews assumed that mammography
screening has a higher benefit for women older than 50 years
and a lower benefit for younger women,11–13,20,28,37,47 because of
the lower test sensitivity of mammography due to higher breast
Figure 4. Overdiagnosis rate reported in systematic reviews of (a) randomised controlled trials and (b) observational studies.
Dashed line: a—Low risk of bias studies, b—Models. Source of cases in denominators: Hamashima, 2016 [20] - not described; Biesheuvel, 2007
[47]—unscreened; Carter, 2015 –mixed (unscreened – 10%, screen expected – 4-76%, screen detected – 17- 31%); Chen, 2017 - unscreened; Duke
Synthesis Group, 2014 [9] – not described (unscreened −29%, screen detected −19%, entire follow up – 11%); The UK Panel, 2012 [6] – screen
detected (16–19%) and entire follow up (10–11%); Myers, 2015 [11] - mixed (screen detected – 19%, entire follow up – 11%); Nelson, 2016 [12] –
not described; Canadian Task Force, 2011 [16] - not described; Lee, 2015 [19] - not described. [Color figure can be viewed at wileyonlinelibrary.com]
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density12,13,29 and, possibly, faster-growing tumours. Myers et al.
(2015) suggested that initiating screening at younger ages proba-
bly results in greater BCM reduction, but the magnitude of this
incremental reduction is uncertain.11 In the high-quality review
by Nelson et al. (2016),12 the reduction in risk of advanced stage
II+ or stage III+ breast cancers was not statistically significant
for women younger than 50 years.
Two included reviews suggest that the rate of overdiagnosis
may be larger among women aged 40–49 years,12,37 with more
than 25% of cases of breast cancer diagnosed among women
in their 40s being low-grade DCIS, of which only 14% if left
untreated could lead to invasive cancer after several decades.47
Although FPR with a single examination was higher for older
women,11,12 the cumulative FPR was higher among women who
Figure 5. False positive cumulative rates with biennial (a) and annual (b) screening. [Color figure can be viewed at wileyonlinelibrary.com]
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initiated screening early (mainly <50 years).12,19,45 The reviews
focusing on women younger than 50 years reported cumulative
FPR of 20–56%.14,37,47 The probability of receiving a certain
diagnostic method was age-dependent: women aged 40–49 years
experience the highest rate of additional imaging,12 and therefore
may face higher radiation-related harms, whereas their rate of
false-positive biopsies is lower than that of older women.12
Regarding BCS-induced deaths, several reviews reported
limited evidence for women screened annually for 10 years
beginning at age 40 years. The estimated number of induced
fatal breast cancers is small (8–25 per 100,000 women
screened in 3 of 4 reviews)12,14,16,45 (Appendix 5), and is
higher with earlier initiation of screening.12
Similarly to the reviews on younger populations, systematic
reviews report inconsistent BCM reduction among women older
than 69 years (Fig. 3d, Appendix 4).8,11,12,16,20,30,49 A review by
Galit et al. (2007) concluded on lower BCM among women
aged 75–84 years who underwent screening compared to those
who did not,8 whereas other reviews concluded on no clear ben-
efit for women older than 70 years.11,12 Regular mammography
has been associated with smaller and earlier-stage tumours
among women older than 74 years, which could also be clini-
cally insignificant.8 The reviews on BCS benefits and harms
among women older than 69 years were based on limited evi-
dence on BCM reduction from RCTs and harms specific to this
age group, and did not report all- cancer or all-cause mortality.
Ultrasonography
No high-quality review (out of 6 included) identified studies
reporting BCM reduction in BCS among the general popula-
tion using ultrasonography alone or in combination with
mammography (Appendix 8). The reviews targeting Asian
populations reported high variability in sensitivity (54–84%),
PPV (0.64–6.4%) and FPR (0.9–19.3%) of ultrasonography,
with specificity of 96–98% and cancer detection rate of 2–3%
per 1,000 screens. The highest-quality reviews12,29 concluded
that ultrasonography is not justified as a supplementary tool
for BCS, because of no solid evidence on its benefits. The
reviews did not report transparently which factors can affect
the accuracy of ultrasonography.
Clinical breast examination
The 10 included systematic reviews that assessed data on clinical
breast examination agreed that the existing data on benefits of
CBE are insufficient, because there is no solid evidence on a statis-
tically significant impact of CBE on BCM (Appendix 8).9,13,16,20
The range for sensitivity of CBE is 28–36% in the community13
and 47–69% in RCTs in all except one review.13,19,20,45 The sensi-
tivity of CBE was improved by spending more time on examina-
tion and by using a thorough technique.13 The specificity of CBE
was above 88% in all the reviews.13,20,45 compared to no screen-
ing, CBE was associated with a higher rate of false-positive biop-
sies13,45 and FPR.9,12 No solid evidence was identified on an
impact of CBE on life expectancy and overdiagnosis.9
Five reviews report no solid evidence on benefits of CBE
combined with screening mammography vs. mammography
alone9,11,12,20,30 (Appendix 8). The reviews’ conclusions varied
from “insufficient evidence on effects of CBE” to “no benefits
of CBE in terms of mortality reduction”; the review by Lee
et al. reported an incremental sensitivity of CBE added to
mammography of 4–6%, with a decrement in specificity of
2%.19 Limited data were available on harms of CBE added to
mammography, with higher FPR and recall rates reported.11,12
Similarly to ultrasonography, the reviews did not report suffi-
ciently on factors affecting the accuracy of CBE, besides an
observation of lower sensitivity of screening in real-world vs.
trial settings.
Breast self-examination
Six reviews were consistent on no benefit of BSE on BCM
(mainly referring to the 3 trials conducted),12,13,31,45 all-cause
mortality,12 or number of cancers detected31 (Appendix 8).
The sensitivity of BSE was 20–41% in a real-world setting vs.
40–89% on silicone models.13,17 The specificity of BSE on sili-
cone models was 66–81%.17 The reviews included reported
harms related to FPR, including false-positive biopsies.12,13,31
Quality of the reviews and factors affecting their
conclusions
The quality of all of the included reviews varied from 1 to
10 on AMSTAR score (Appendix 9). The reviews were scored
the highest on the attributes related to an adequate search
approach, description of the included studies and combining
the results, and the lowest on reporting conflicts of interest,
assessing publication bias, including grey literature and report-
ing excluded studies (Fig. 6). Multiple regression analysis was
used to test if a year of publication, targeting high-income
country (vs. none), declaring funding, or including the evidence
only from controlled trials significantly predicted AMSTAR
Figure 6. Quality of systematic reviews reporting benefits and/or
harms of breast cancer screening.
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score of the reviews. The results of the regression indicated that
all four factors explained 22% of the variance (R2 = 0.22, F
(6,45) = 2.09, p = 0.07) with funding and target country being
not significant factors. The year of publication (β = 0.12,
p < 0.05) and type of evidence included (β = −0.82, p < 0.05)
explained 16% of variance (R2 = 0.16, F(2,49) = 4.61, p = 0.01)
with model being a better-fit than the univariate analyses.
The results of uni- and multi-variate regressions did not
identify significance of such factors as AMSTAR score, date of
publication, funding, using qualitative or meta-synthesis, or
reporting benefits, harms, or both in the conclusions of the
reviews on mammography screening (p > 0.05). The conclu-
sions of the reviews reporting similar statistical results were
not always identical and may be based on interpretation of
statistics, choice of the main outcomes, rigorousness of inclu-
sion criteria and source of evidence. The conclusions of the
reviews updated periodically with the new evidence (Appendix
10) did not differ substantially from the previous versions. The
publications from one cluster mainly reported similar values
for outcomes.
While based on the same RCTs, reviews were inconsistent
in the conclusions of trials’ biases either in relation to benefits
or harms estimation (Appendix 11). The reviews of observa-
tional evidence frequently included different studies; the qual-
ity of most of them was judged as fair or moderate and the
selection bias was the main risk (Appendix 11).
Discussion
Systematic reviews of BCS focus on mammography more than
on the other screening approaches, and evaluate benefits of
screening more frequently than harms. The available system-
atic reviews of either benefits or harms of BCS mainly target
high-income countries; all RCTs and most of the observa-
tional studies on screening mammography were conducted in
high-income jurisdictions, on ultrasonography in the USA
and Asia, on CBE in North America and Asia, and on BSE in
North America, Europe, the Russian Federation and Asia.
The reviews’ conclusions on any of the screening approaches
were not seen to evolve with time, although some recent updates
of the guidelines reported lower importance of mammography
screening for younger women compared to earlier versions.12,50
We also did not observe a difference in the conclusions of the
narrative and systematic reviews. The reviews with high
AMSTAR scores and close publication or search date could
reach contradictory conclusions on the benefit-to-harm ratio
of mammography screening and the justification for its imple-
mentation. We found no evidence that variability in the
reviews’ conclusions was related to objective reasons (search
date, rigorousness of inclusion criteria, choice of an outcome,
source of evidence). The reviews of more rigorous evidence
generally reported both lower benefits and lower harms. We
did not see major additive value from the new reviews or
updates of the previous reviews on BCS. We conclude that
until new high-quality cohort or RCT results are published,
additional reviews on BCS with mammography, ultrasonogra-
phy, CBE, or BSE would not be of great value.
Summaries of evidence: mammography
The reviews are consistent in reduction in BCM among the
general population and women aged 50–69 years, but not all-
cancer or all-cause mortality. Both all-cancer and all-cause
mortality may serve as the least biased outcomes of the efficacy
of screening, avoiding possible mortality misclassifications.
However, they may not be sensitive enough to detect the mag-
nitudes in effects. Thus, disease-specific mortality may present
the pure effect of the screening programme, while all-cancer
and all-cause mortality may be considered in health-care
resource allocation and priority setting, enabling comparison of
the relative value of screening mammography with other
health-care innovations improving survival of the population.
The pure benefits and harms of mammography remain
heterogeneous. BCS trials are highly diverse in their protocol
designs, adherence and evaluations; combining the outcomes
of the RCTs into meta-analyses generates the expectations,
but does not predict the outcomes of a specific program
(which can either fail or succeed reaching higher effectiveness
than meta-synthesised efficacy). Differences between reviews
in quality assessment comprise not only identification of bias
but also the assignment of overall quality scores, leading to
variation in inclusion of RCTs. Subsequently, results of the
reviews vary and conclusion were inconsistent. In general, the
assessed reviews of RCTs have greater similarity in included
studies but larger variability in quality assessment while
reviews on observational studies show an opposite trend. If
this overview will include only reviews incorporated the qual-
ity of studies in their conclusions, the disagreements among
the reviews would remain. The impact of screening mammog-
raphy on stage shift – the most potent intermediate predictor
of screening efficacy – was positive for stage III+ breast can-
cer. BCM increases with progressing tumour stage,51 and
therefore reduction of advanced tumours should improve
patients’ survival. Tabar et al. (2015) calculated that BCM
reduction was reaching 28% in the trials achieving 20% or
more reduction in advance cancers.52 Since BCS programs are
long-term planned and costly, detection of advanced cancers
should serve as an early indicator of the possible success of
the pilot BCS program.
The effectiveness of BCS relates to multiple parameters,
including treatment access and efficacy. Regarding access, the
health-care settings depicted in RCTs included in systematic
reviews may reflect the current situation in LMICs, allowing
an approximation of the expected benefits and harms for
jurisdictions with limited resources. Furthermore, breast can-
cer survival also has improved dramatically through the
decades due to treatment advances, with age-standardised
5-year survival reaching 85% or higher in 17 high-income
countries and 80% or higher in 34 countries worldwide,53
which may diminish the benefits of mammography screening.
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If efficacy of late-stage treatments for breast cancer improves
more, the clinical benefit of screening may decrease. Concur-
rently, the accuracy of mammography may also have improved
through the years, favouring the benefit-to-harm ratio. Deci-
sions on the rationale for screening should always be a balanced
choice of the intervention able to offer the highest benefits with
minimum harms, and preferably lower costs.
For women younger than 50 years or older than 69 years,
the reviews were not consistent in their conclusions on BCM
reduction, with no impact of screening on all-cancer mortality
reported. For younger women, most reviews show no impact
of mammography screening on early breast cancer detection.
The harms may be also higher among younger women (radia-
tion exposure and FPR) and older women (overdiagnosis,
because of shorter life expectancy); thus, the evidence col-
lected by included reviews is not consistent on benefit-
to-harm ratio for these age groups.
There was no consistency in determinants of higher benefits
and lower harms of screening mammography, although double
reading may improve sensitivity if the recall decision is based
on at least one reader. DCIS is frequently detected and treated
during mammography screening. Considering that relative
survival with DCIS reached 100% even after 15 years of
follow-up,51 the quality control system should advise on clear
and non-aggressive management of screen-detected DCIS.
The benefit-to-harm ratio may also be improved with avail-
ability of previous screening results. The guidelines on strict
quality control and management of non-cancerous lesions
could be more important in countries without a national
screening provider, like the USA, where harms may be higher
than in other countries.
Benefits to harm ratios of mammography screening among
women 50 to 59 year old could not remain the same in all juris-
dictions. As indicated, effective screening requires organised
programs and may vary with disease incidence, population char-
acteristics and structures of financial and health-care systems.
Considering the high variability in determinants of benefits and
harms of screening, implementing BCS programmes without
proper evaluation in these countries is risky, and so the
results of the reviews should be extrapolated to LMICs with
caution.
For LMICs with high breast cancer incidence and mortality,
available early detection programmes, and sufficient capacity,
piloting mammography screening among women aged
50–69 years should be combined with evaluation of imple-
mentation outcomes before programme scale-up.
Summaries of evidence: ultrasonography, clinical breast
examination and breast self-examination
The reviews agree on no solid evidence of mortality reduction
with ultrasonography and CBE, and evidence of no effect and
higher harms with BSE. Although our review could not sum-
marise evidence from the reviews on reduction in advance
breast cancers with CBE, the IARC Handbook on BCS
concluded on sufficient strength of evidence regarding shifts in
the stage distribution of tumours detected.54 Because mortality
reduction with ultrasonography and CBE screening is not con-
firmed while evidence of potential harms exists, population
programmes applying these approaches in countries without
access to mammography are questionable. The sensitivity of
both methods vary significantly, and real-world implementation
may not reach the accuracy reported in trials. The accuracy of
these screening approaches is provider-dependent; although
CBE is perceived as a low-cost modality, its implementation in
communities may entail substantial expenses related to quality
assurance, invitations and opportunity costs.
Because of the lack of solid evidence, the benefits and harms
of ultrasonography and CBE should be explored further within
pilot studies. We consider that appropriate implementation
studies on these interventions are necessary even in countries
with limited resources, because opportunistic benefits and costs
may affect the functioning of the other health programmes.
Research and information gaps
We consider that additional reviews should be discouraged
until new original evidence is available. The quality of reviews
could be better standardised if the authors were systematically
required to apply quality grading instruments to their submit-
ted manuscripts.
More original research on benefits and harms of CBE,
ultrasonography and mammography screening among older
women is required, which is especially important considering
increasing life expectancy. Research targeted at improving the
benefit-to-harm ratio of BCS should be encouraged.
The lack of primary and secondary research in LMICs does
not enable extrapolation of the evidence to these settings.
Because all screening approaches are operator-dependent,
high-quality studies are required to gather effectiveness and
implementation outcomes of the piloted BCS programmes.
Limitation
Considering the large scope of this systematic review, it is pos-
sible that we missed some of the important information
despite the comprehensive approach to the evidence search
and data extraction. We noted the limitations of using
AMSTAR for judging the quality of reviews on cancer screen-
ing; some questions on AMSTAR may not be important for
reviews of screening studies (such as conflicts of interest of
the included studies), low AMSTAR scores may be related to
journals’ editorial policies on reporting, and high AMSTAR
scores may not always mean the absence of biases.
Conclusion
Mammography screening for women aged 50 to 69 years results
to decrease in BCM, but not all- cancer and all-cause mortality.
It also causes harms, such as overdiagnosis and FPR, which are
higher with more frequent screening. The conclusions of the
reviews on benefits and harms of mammography were not
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consistent for the other age groups. No clear determinants of
benefits and harms of mammography screening were identified.
The other BCS approaches, such as US, CBE, BSE, cause harms
but do not have sufficient evidence on mortality decrease.
Systematic reviews of mammography screening, mainly
targeting high-income countries, are discordant in their inter-
pretation of benefits and harms of screening, and their ratio.
Their conclusions are not related to their AMSTAR quality
score, funding, objectives or the year of publication.
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Definitions
Accuracy—ability of a test to discriminate between the target
condition and health, such as sensitivity, specificity and test
predictive values;
Ductal carcinoma in situ—non-invasive or pre-invasive
breast cancer;
False-positive rate—proportion or percentage of screening
tests in which a test result improperly indicates presence of
breast cancer when in reality it is not present;
Overdiagnosis—the diagnosis of a tumour that would not
go on to cause symptoms or death in the woman’s lifetime;
Positive Predictive Value—probability that a woman with a
positive screening test truly has cancer.
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